How many molecular subtypes? Implications of the unique tumor principle in personalized medicine

Expert Review of Molecular Diagnostics

Volumn 12, Issue 6, 2012, Pages 621-628

  Ogino, Shuji ^a,b,c,d   Fuchs, Charles S ^a,b,c   Giovannucci, Edward ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

genomics; holistic; intratumor heterogeneity; molecular classification; molecular pathological epidemiology; MPE; neoplasia; phenome; systems biology; tumor host interaction; unique tumor paradigm

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEOME; TRANSCRIPTOME;

AGING; BIOACCUMULATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER REGISTRY; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; DIET; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EXTRACELLULAR MATRIX; GENETIC VARIABILITY; GENOME ANALYSIS; HOST CELL; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LIFESTYLE; METABOLOME; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; OBESITY; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SOMATIC MUTATION; TUMOR CELL; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIUM;

GENE-ENVIRONMENT INTERACTION; GENETIC HETEROGENEITY; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84864579906     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.46     Document Type: Review

References (108)

1. Baudhuin LM, Donato LJ, Uphoff TS. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev. Mol. Diagn. 12(1), 25-37 (2012).
2. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
3. Metodiev MV. Biomarkers research in Europe: Focus on personalized medicine. Expert Rev. Mol. Diagn. 11(7), 689-690 (2011).
4. Hamilton SR. Targeted therapy of cancer: New roles for pathologists in colorectal cancer. Mod. Pathol. 21(Suppl. 2), S23-S30 (2008).
5. Gulley ML, Braziel RM, Halling KC et al. Clinical laboratory reports in molecular pathology. Arch. Pathol. Lab. Med. 131(6), 852-863 (2007).
6. Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: Report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: A stakeholder summit. Am. J. Clin. Pathol. 135(5), 668-672 (2011).
7. Funkhouser WK, Lubin IM, Monzon FA et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: A report of the Association for Molecular Pathology. J. Mol. Diagn. 14(2), 91-103 (2012).
8. Febbo PG, Ladanyi M, Aldape KD et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J. Natl Comp. Canc. Netw. 9(Suppl. 5), S1-S32; quiz S33 (2011).
9. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11(10), 726-734 (2011).
10. Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: Complex simplicity. J. Clin. Oncol. 29(10), 1382-1391 (2011).
11. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8(12), 686-700 (2011).
12. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 60(1), 116-129 (2011).
13. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J. Natl Cancer Inst. 102(6), 365-367 (2010).
14. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol. 8(12), 711-719 (2011).
15. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut 60(3), 397-411 (2011).
16. Begg CB. A strategy for distinguishing optimal cancer subtypes. Int. J. Cancer 129(4), 931-937 (2011).
17. Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am. J. Epidemiol. (2012) (In press).
18. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
19. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 10(1), 13-27 (2008).
20. Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43(8), 768-775 (2011).
21. Siegmund KD, Marjoram P, Tavare S, Shibata D. High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. PLoS ONE 6(6), e21657 (2011).
22. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 476(7359), 163-169 (2011).
23. Allen M, Louise Jones J. Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J. Pathol. 223(2), 162-176 (2011).
24. Soto AM, Sonnenschein C. The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory. Bioessays 33(5), 332-340 (2011).
25. Lee HO, Silva AS, Concilio S et al. Evolution of tumor invasiveness: The adaptive tumor microenvironment landscape model. Cancer Res. 71(20), 6327-6337 (2011).
26. Xia D, Wang D, Kim SH, Katoh H, Dubois RN. Prostaglandin E(2) promotes intestinal tumor growth via DNA methylation. Nat. Med. 18(2), 224-226 (2012).
27. O'Hagan HM, Wang W, Sen S et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell 20(5), 606-619 (2011).
28. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
29. Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339), 467-472 (2011).
30. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
31. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075 (2008).
32. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006).
33. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
34. Jiao Y, Shi C, Edil BH et al. DAXX/ ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199-1203 (2011).
35. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897), 1807-1812 (2008).
36. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539-542 (2011).
37. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360), 298-303 (2011).
38. Parsons DW, Li M, Zhang X et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331(6016), 435-439 (2011).
39. Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature 470(7333), 214-220 (2011).
40. Jones S, Wang TL, Shih IeM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330(6001), 228-231 (2010).
41. Coppede F. Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation. Cancer Lett. doi:10.1016/j. canlet.2011.12.030 (2012) (Epub ahead of print).
42. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: Past, present and future. Patholog. Res. Int. 2011, 902674 (2011).
43. Hughes LA, Khalid-De Bakker CA, Smits KM et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochim. Biophys. Acta 1825(1), 77-85 (2012).
44. Berman HK, Gauthier ML, Tlsty TD. Premalignant breast neoplasia: A paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications. Cancer Prev. Res. (Phila.) 3(5), 579-587 (2010).
45. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev. Res. (Phila.) 3(11), 1361-1364 (2010).
46. Dornan D, Settleman J. Dissecting cancer heterogeneity. Nat. Biotechnol. 29(12), 1095-1096 (2011).
47. Marusyk A, Almendro V, Polyak K. Intratumor heterogeneity: A looking glass for cancer. Nat. Rev. Cancer 12(5), 323-334 (2012).
48. Dalerba P, Kalisky T, Sahoo D et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol. 29(12), 1120-1127 (2011).
49. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 472(7341), 90-94 (2011).
50. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6(12), 924-935 (2006).
51. Loeb LA. Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat. Rev. Cancer 11(6), 450-457 (2011).
52. Amos-Landgraf JM, Irving AA, Hartman C et al. Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms. Proc. Natl Acad. Sci. USA 109(6), 2060-2065 (2012).
53. Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J. Pathol. 187(4), 433-438 (1999).
54. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812-1820 (2010).
55. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105(7), 2652-2657 (2008).
56. Liao X, Morikawa T, Lochhead P et al. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin. Cancer Res. 18(8), 2257-2268 (2012).
57. Monzon FA, Ogino S, Hammond EH, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med. 133(10), 1600-1606 (2009).
58. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 138(6), 2073-2087.e3 (2010).
59. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361(25), 2449-2460 (2009).
60. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999).
61. Samowitz W, Albertsen H, Herrick J et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129(3), 837-845 (2005).
62. Nosho K, Irahara N, Shima K et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 3(11), e3698 (2008).
63. Hinoue T, Weisenberger DJ, Lange CP et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22(2), 271-282 (2012).
64. Estecio MR, Gharibyan V, Shen L et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2(5), e399 (2007).
65. Ogino S, Kawasaki T, Nosho K et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer. Int. J. Cancer 122, 2767-2773 (2008).
66. Ibrahim AE, Arends MJ, Silva AL et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 60(4), 499-508 (2011).
67. Sunami E, De Maat M, Vu A, Turner RR, Hoon DS. LINE-1 hypomethylation during primary colon cancer progression. PLoS ONE 6(4), e18884 (2011).
68. Baba Y, Huttenhower C, Nosho K et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol. Cancer 9, 125 (2010).
69. Suehiro Y, Wong CW, Chirieac LR et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and p53 pathways in colorectal carcinoma. Clin. Cancer Res. 14(9), 2560-2569 (2008).
70. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: Possible associations with male sex and KRAS mutations. J. Mol. Diagn. 8, 582-588 (2006).
71. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654-18659 (2007).
72. Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 56, 1409-1416 (2007).
73. Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 16(6), 1845-1855 (2010).
74. Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl Cancer Inst. 100, 1734-1738 (2008).
75. Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9), 1847-1854 (2011).
76. Hughes LA, Williamson EJ, Van Engeland M et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: A pooled analysis. Int. J. Epidemiol. doi:10.1093/ije/dys055 (2012) (Epub ahead of print).
77. Ogino S, Giovannucci E. Lifestyle factors and colorectal cancer microsatellite instability: Molecular pathological epidemiology science, based on unique tumor principle (commentary). Int. J. Epidemiol. doi:10.1093/ije/ dys076 (2012) (Epub ahead of print).
78. Kuller LH. The twenty-first century epidemiologist: Need for different training? Am. J. Epidemiol. (2012) (In Press).
79. Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E. Need for molecular pathological epidemiology (MPE) and MPEist in 21st century: Keeping up with next generation science. Am. J. Epidemiol. (2012) (In Press).
80. Hughes LA, Simons CC, Van Den Brandt PA et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS ONE 6(4), e18571 (2011).
81. Boyle T, Fritschi L, Heyworth J, Bull F. Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am. J. Epidemiol. 173(10), 1183-1191 (2011).
82. Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J. Natl Comp. Canc. Netw. 9(11), 1293-1302 (2011).
83. Chen D, Song S, Lu J et al. Functional variants of -1318T>G and -673C>T in c-Jun promoter region associated with increased colorectal cancer risk by elevating promoter activity. Carcinogenesis 32(7), 1043-1049 (2011).
84. Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: THE Cancer Prevention Study-II Nutrition Cohort. J. Clin. Oncol. 30(1), 42-52 (2012).
85. Boyle T, Heyworth J, Bull F, Mckerracher S, Platell C, Fritschi L. Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer. Cancer Causes Control 22(12), 1647-1658 (2011).
86. Gehoff A, Basten O, Sprenger T et al. Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. Am. J. Surg. Pathol. 36(2), 202-213 (2012).
87. Iwagami S, Baba Y, Watanabe M et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann. Surg. Oncol. doi:10.1245/s10434-011-2176-3 (2011) (Epub ahead of print).
88. Esteban S, Moya P, Fernandez-Suarez A, Vidaurreta M, Gonzalez-Peramato P, Sanchez-Carbayo M. Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer. Tumour Biol. 33(2), 337-346 (2012).
89. Limburg PJ, Limsui D, Vierkant RA et al. postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol. Biomarkers Prev. 21(4), 681-684 (2012).
90. Swedlow JR, Lewis SE, Goldberg IG. Modelling data across labs, genomes, space and time. Nat. Cell Biol. 8(11), 1190-1194 (2006).
91. Ghosh S, Matsuoka Y, Asai Y, Hsin KY, Kitano H. Software for systems biology: From tools to integrated platforms. Nat. Rev. Genet. 12(12), 821-832 (2011).
92. Papp B, Notebaart RA, Pal C. Systems-biology approaches for predicting genomic evolution. Nat. Rev. Genet. 12(9), 591-602 (2011).
93. Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip. Rev. Syst. Biol. Med. 3(6), 619-627 (2011).
94. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
95. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
96. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
97. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
98. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
99. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
100. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
101. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315), 596-599 (2010).
102. Straussman R, Morikawa T, Shee K et al. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature (2012) (In Press).
103. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: Calgb 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26(33), 5360-5367 (2008).
104. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J. Natl Comp. Canc. Netw. 5(Suppl. 2), S1-S29; quiz S30 (2007).
105. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387), 100-103 (2012).
106. Fox EJ, Loeb LA. Lethal mutagenesis: Targeting the mutator phenotype in cancer. Semin. Cancer Biol. 20(5), 353-359 (2010).
107. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: How personal should we go? Nat. Rev. Clin. Oncol. 9(2), 87-97 (2011).
108. La Thangue NB, Kerr DJ. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8(10), 587-596 (2011).